Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Laura Huppert, MD, BA
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03971409CT.gov Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Invasive Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ivuxolimab (this asset) | Laura Huppert, MD, BA | P2 | CCC · 53 |
| Tamoxifen | University of California, San Francisco | P4 | BBB |
| Letrozole | Emory University | P4 | BBB |
| Exemestane | University of California, San Francisco | P4 | BBB |
| Anastrozole | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Fulvestrant | Massachusetts General Hospital | P2 | BB |
| Carboplatin | Baylor Breast Care Center | P3 | BB |
| Trastuzumab | Massachusetts General Hospital | P3 | BB |
| Pertuzumab | Baylor Breast Care Center | P3 | BB |
+42 more in the Invasive Breast Carcinoma cohort
Other indications for Ivuxolimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer | — | P3 | BB · 64 |
| Urothelial Carcinoma | — | P3 | B · 57 |
| Renal Cell Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ivuxolimab in Invasive Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ivuxolimab-invasive-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →